Dec. 9 at 5:35 PM
$RVVTF To begin with, RVVTF had a lot of potential. In biotech, companies with similar potential typically have valuations above
$100 million. This was mismanaged—not entirely MF’s fault, as it is a small, budget-constrained company. Hopefully the new and bigger players can pull something together, something meaningful. We need good news no doubt, but we need minimum 5 cents before that so that most of us early investors can reach break-even.